Implementation and patient outcomes of a pediatric COVID-19 monoclonal antibody program.

ABSTRACT:

Background

The severity and reach of the COVID-19 pandemic drove the development of various therapeutic approaches to combat SARS-CoV-2, including several neutralizing monoclonal antibody (mAb) therapies. A January 2021 pediatric consensus statement opposed routine use and recommended individualized risk assessments when considering COVID-19 mAb therapies in children and adolescents due to limited data. This report describes the implementation of a mAb referral process and clinical outcomes of patients who received a mAb infusion in a pediatric hospital.

Methods

We developed a tiered allocation system based on underlying medical conditions and incorporated it into a standardized COVID-19 mAb referral and approval process. Demographics and clinical data were collected on all

SUBMITTER: Blind JE 

PROVIDER: S-EPMC9619745 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature